The company said revenue for Q1 2025 (quarter ended March 31) decreased 5% from $2,341 million a year earlier to $2,223 million, and it cited the sale of TRANZACT as a factor in the decline. Organic revenue increased 5%.

1. 01

   The company said revenue for Q1 2025 (quarter ended March 31) decreased 5% from $2,341 million a year earlier to $2,223 million, and it cited the sale of TRANZACT as a factor in the decline. Organic revenue increased 5%.

2. 02

   WTW said Income from Operations for Q1 2025 was $432 million and Operating Margin was 19.4%, up 740 basis points from 12.0% a year earlier. Adjusted Operating Margin was 21.6%, up 100 basis points from 20.6%.

3. 03

   The company said Diluted EPS for Q1 2025 was $2.33, up 27% from $1.83 a year earlier. Adjusted Diluted EPS was $3.13, unchanged from the prior year. Net Income was $239 million, compared with $194 million a year earlier.

4. 04

   WTW said cash used in operating activities for Q1 2025 was $35 million, and free cash flow was $(86) million, a decrease of $50 million from $(36) million a year earlier. It also said it repurchased 607,221 shares for $200 million in the same quarter.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.